Re: Minimizing risks to patients by improving presentation of clinical trial results in geographic atrophy trials (Ophthalmol Retina. 2022;6:337-338)
Ophthalmol Retina
.
2022 Nov;6(11):1109.
doi: 10.1016/j.oret.2022.08.010.
Authors
David S Liao
1
,
Federico V Grossi
2
,
Charles C Wykoff
3
,
Ramiro M Ribeiro
2
,
Philip J Rosenfeld
4
,
Srinivas R Sadda
5
Affiliations
1
Retina-Vitreous Associates Medical Group, Los Angeles, California. Electronic address: dliao@laretina.com.
2
Apellis Pharmaceuticals, Inc, Waltham, Massachusetts.
3
Retina Consultants of Texas, Houston, Texas.
4
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.
5
Department of Ophthalmology, University of California - Los Angeles, Los Angeles, California; Doheny Eye Institute, Pasadena, California.
PMID:
36334931
DOI:
10.1016/j.oret.2022.08.010
No abstract available
Publication types
Letter
Comment
MeSH terms
Clinical Trials as Topic
Geographic Atrophy* / diagnosis
Humans
Retina